Which GLP-1 Has Most Weight Loss? Clinical Evidence & Genetics

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Clinical trials show tirzepatide produces greater average weight loss than semaglutide—approximately 21-22% body weight reduction versus 15-17%—but this comparison masks critical individual variation. Real-world outcomes depend on metabolism, genetics, dosing adherence, and lifestyle factors beyond medication efficacy alone.

Selecting the 'most effective' GLP-1 requires moving beyond headline clinical data to understand your metabolic profile and genetic context. PlexusDx supports precision-wellness conversations by revealing how your peptide pathway genetics and biomarkers may influence individual medication response.

Clinical Trial Data: Comparing Average Weight Loss Outcomes

Tirzepatide clinical trials (SURMOUNT series) demonstrated mean weight loss of 21-22% at maximum doses in patients with obesity and type 2 diabetes. Semaglutide trials (STEP series) showed 15-17% average weight loss at highest doses. These averages represent population-level efficacy, not individual predictability.

These trials enrolled carefully selected participants with controlled baseline conditions and high protocol adherence—factors rarely replicated in clinical practice. Real-world outcomes vary widely even among patients on identical medications and doses, suggesting individual biological factors significantly influence response.

Why Individual Weight Loss Response Varies: A Biomarker Framework

Two patients on the same GLP-1 dose may lose 5% versus 25% body weight due to differences in insulin sensitivity, baseline metabolic rate, GLP-1 receptor expression, appetite regulation genetics, and GIPR (glucose-dependent insulinotropic polypeptide receptor) signaling. Population averages obscure this individual heterogeneity.

Biomarker/Factor	Influence on GLP-1 Response
Baseline Insulin Resistance	Higher baseline IR may show greater initial weight loss; metabolic state at treatment start predicts trajectory
GLP-1 Receptor Genetics (rs6923761)	Genetic variants may influence GLP-1R expression and downstream satiety signaling efficiency
GIPR Variants (rs1800437)	GIPR co-activation enhances weight loss; genetic predisposition in GIPR pathway affects tirzepatide vs semaglutide relative benefit
FTO Gene Status (rs9939609)	Risk alleles associated with increased appetite drive; may moderate treatment response independent of medication choice
MC4R Variants (rs17782313)	Involved in melanocortin appetite regulation; genetic context may influence satiety signaling from GLP-1 agonists

Tirzepatide Versus Semaglutide: Beyond the Average Comparison

Tirzepatide activates both GLP-1 and GIPR, while semaglutide targets GLP-1 alone. This dual mechanism typically yields greater weight loss averages, but approximately 30-40% of semaglutide users achieve excellent outcomes, and some tirzepatide responders experience modest results. Mechanism alone does not determine individual efficacy.

Provider selection between these compounds should incorporate baseline metabolic markers (fasting glucose, C-peptide, lipid profile), patient genetics (especially GIPR pathway variants), gastrointestinal tolerance history, and cardiovascular risk profile—not weight-loss averages alone. Dose escalation and protocol adherence equally influence outcomes.

Who Benefits Most: Clinical Context and Candidacy Considerations

Patients with severe insulin resistance, baseline fasting glucose 110+ mg/dL, and family history of type 2 diabetes may see larger weight loss percentages with tirzepatide's dual mechanism. However, those with normal insulin sensitivity or contraindications to GIPR activation may achieve equivalent or superior outcomes with semaglutide.

Before starting any GLP-1 medication, comprehensive metabolic screening (fasting glucose, insulin, lipid panel, HbA1c), assessment of gastrointestinal and cardiovascular risk, and provider conversation about realistic individual expectations are essential. Genetic insights into peptide pathway predispositions can contextualize these discussions but do not predict exact outcomes.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test examines key variants in GIPR and FTO, and MC4R pathways to help provide context about your inherited predispositions in appetite regulation and glucose sensing. These insights may help inform personalized conversations with your provider about which GLP-1 class could align with your metabolic profile.

The genetic test reveals whether you carry risk variants in GIPR signaling (relevant to tirzepatide dual-mechanism benefit), GLP-1 receptor efficiency, and appetite-drive genes. These predispositions do not predict exact weight loss percentages—individual response depends on adherence, diet, exercise, and numerous unmeasured factors—but genetic context supports more informed decision-making.

Understanding your genetic predispositions alongside clinical biomarkers (baseline insulin, metabolic rate, cardiovascular status) enables you and your provider to design a realistic treatment plan tailored to your biology, not population averages. This precision-wellness approach increases the likelihood of sustained success.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Does the trial data really show tirzepatide outperforming semaglutide on weight loss?

On averages, yes. The article puts tirzepatide's mean result at maximum dose in the low twenties as a percentage of body weight, against the mid-teens for semaglutide. Its own caveat matters just as much: those are population averages from tightly controlled studies with selected participants and high protocol adherence, conditions it says are rarely reproduced in ordinary practice. Which agent suits an individual remains a prescriber's judgment.

Why can two people on the same GLP-1 dose end up with completely different results?

The article says the spread is wide enough that two patients on identical doses can land anywhere from roughly 5 percent to 25 percent of body weight lost. It attributes that range to differences in insulin sensitivity, baseline metabolic rate, receptor expression, and appetite regulation, none of which show up in a headline average. That is its core argument for reading population figures as context rather than as a forecast.

What is mechanistically different between tirzepatide and semaglutide?

Tirzepatide acts at two receptors while semaglutide acts at one. The article explains that tirzepatide activates both the GLP-1 and the GIP receptor, whereas semaglutide targets GLP-1 alone, and credits that dual action for the higher average outcomes. It immediately qualifies the point, noting that many semaglutide users do very well and some tirzepatide users see modest results, so mechanism alone does not settle individual efficacy.

What should a provider weigh besides the headline averages when choosing between these two?

The article lists baseline metabolic markers including fasting glucose, C-peptide and a lipid profile, together with gastrointestinal tolerance history and cardiovascular risk. It argues that selection should rest on that clinical picture rather than on trial averages alone. It also points out that how the dose is escalated and how consistently a patient stays on treatment influence the outcome just as much as which compound was chosen.

What screening does the article call for before starting either medication?

It calls for comprehensive metabolic screening beforehand, naming fasting glucose, insulin, a lipid panel and HbA1c. Alongside the labs it wants an assessment of gastrointestinal and cardiovascular risk, plus an explicit conversation with the provider about what a realistic individual outcome looks like. The article treats that expectation-setting step as no less important than the bloodwork itself.

Medical and Editorial Standards

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.